Evidence map›Paper›PMID 41287114›Full record

ArticlePneumonia (Nathan Qld.)2025

Individualized treatment rule for early steroid use in hospitalized patients with community acquired pneumonia: a cohort study.

Yewande E Odeyemi, Allison M LeMahieu, Erin F Barreto, Hemang Yadav, Ognjen Gajic, Phillip Schulte

Abstract read
In one paragraph

Article in Pneumonia (Nathan Qld.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yewande E OdeyemiDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. odeyemi.yewande@mayo.edu.
Allison M LeMahieuDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, 55905, USA.
Erin F BarretoDepartment of Pharmacy, Mayo Clinic, Rochester, MN, 55905, USA.
Hemang YadavDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Ognjen GajicDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Phillip SchulteDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, 55905, USA.

Funding

Predicting and Preventing Acute Respiratory Distress Syndrome after Hematopoietic Stem Cell TransplantationK23HL151671 · NHLBI · MAYO CLINIC ROCHESTER · PI YADAV, HEMANG · 2021 to 2025
$813k
Individualizing Steroid Use in Pneumonia (Supplement)K23HL168212 · NHLBI · MAYO CLINIC ROCHESTER · PI Yewande Odeyemi · 2023 to 2026
$751k
National Institute of Health K23HL151671National Institute of Health K23HL168212NHLBI NIH HHS K23 HL151671NHLBI NIH HHS K23 HL168212
6 · The paper itself

Abstract

backgroundCurrent evidence on an optimal patient selection strategy for adjunctive steroids to curb excessive inflammation in community acquired pneumonia (CAP) is limited. An individualized treatment rule (ITR) customizes treatment recommendations based on individual patient characteristics. The objective of this study was to develop an ITR for early steroid use in hospitalized patients with CAP.

methodsUsing a single center cohort of hospitalized patients with CAP from 2009 to 2019, we developed a single decision ITR to initiate or not initiate steroids early (within 24 h) after admission. The primary outcome of interest was hospital-free days measured at 28 days. Regression-based learning with LASSO selected a model estimating expected outcomes of potential intervention with steroids individualized to predictors. The optimal ITR was compared to other treatment rules including as observed in the data.

resultsA total of 4379 patients were included in this cohort with 1412 (32%) patients receiving steroids within 24 h of hospital admission. Compared to observed practice, an optimal ITR was associated with increased hospital-free days (mean rate [95% confidence interval (CI)]: 21.74 [21.52, 21.95] versus 22.31 [22.11, 22.51]). The optimal ITR for the secondary outcomes including ventilator-free days, mortality and need for advanced respiratory failure support and/or mortality revealed better estimates compared to what was observed in the data. However, there was a lack of consistent performance when applying the advanced respiratory failure and/or mortality (a secondary outcome) ITR to other outcomes (inconsistency of results across models).

conclusionAn ITR for early steroid use in hospitalized patients with CAP did not consistently improve clinical outcomes.

Indexed as

Clinical outcomesCommunity-acquired pneumoniaCorticosteroidIndividualized treatment rule

Identifiers

PMID41287114
PMCPMC12645675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.